Henrique da Silva Ferrão Nascimento

Dr. Henrique da Silva Ferrão Nascimento

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2009 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
FPFátima Paiva-Martins
Fátima Paiva-Martins
JFJoao Fernandes
Joao Fernandes
Susana RochaSusana Rocha
Susana Rocha
HNHenrique da Silva Ferrão Nascimento
Henrique da Silva Ferrão Nascimento
Rui VitorinoRui Vitorino
Rui Vitorino
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva

17 March 2010 in Carbohydrate Polymers
Verified
Journal Article
Closed access
JFJoao Fernandes
Joao Fernandes
PEPeter Eaton
Peter Eaton
HNHenrique da Silva Ferrão Nascimento
Henrique da Silva Ferrão Nascimento
MGMaria S. Gião
Maria S. Gião
Oscar RamosOscar Ramos
Oscar Ramos
FMFrancisco Malcata
Francisco Malcata

11 November 2008 in Biomacromolecules
Verified
Journal Article
Closed access
JFJoao Fernandes
Joao Fernandes
PEPeter Eaton
Peter Eaton
HNHenrique da Silva Ferrão Nascimento
Henrique da Silva Ferrão Nascimento
Luís BeloLuís Belo
Luís Belo
Susana RochaSusana Rocha
Susana Rocha
FMFrancisco Malcata
Francisco Malcata

24 November 2013 in Disease Markers
Verified
Journal Article
Open access
PDF file
MSMaria Do Sameiro-Faria
Maria Do Sameiro-Faria
SRSandra Ribeiro
Sandra Ribeiro
Elisio CostaElisio Costa
Elisio Costa
DMDenisa Mendonça
Denisa Mendonça
LTLaetitia Teixeira
Laetitia Teixeira
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
Background.End-stage renal disease (ESRD) patients under hemodialysis (HD) have high mortality rate. Inflammation, dyslipidemia, disturbances in erythropoiesis, iron metabolism, endothelial function, and nutritional status have been reported in these patients. Our aim was to identify any significant association of death with these disturbances, by performing a two-year follow-up study.Methods and Results.A large set of data was obtained from 189 HD patients (55.0% male; 66.4 ± 13.9 years old), including hematological data, lipid profile, iron metabolism, nutritional, inflammatory, and endothelial (dys)function markers, and dialysis adequacy.Results.35 patients (18.5%) died along the follow-up period. Our data showed that the type of vascular access, C-reactive protein (CRP), and triglycerides (TG) are significant predictors of death. The risk of death was higher in patients using central venous catheter (CVC) (Hazard ratio [HR] =3.03, 95% CI = 1.49–6.13), with higher CRP levels (fourth quartile), compared with those with lower levels (first quartile) (HR = 17.3, 95% CI = 2.40–124.9). Patients with higher TG levels (fourth quartile) presented a lower risk of death, compared with those with the lower TG levels (first quartile) (HR = 0.18, 95% CI = 0.05–0.58).Conclusions.The use of CVC, high CRP, and low TG values seem to be independent risk factors for mortality in HD patients.

1 July 2009 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
Susana RochaSusana Rocha
Susana Rocha
Elisio CostaElisio Costa
Elisio Costa
Susana CoimbraSusana Coimbra
Susana Coimbra
HNHenrique da Silva Ferrão Nascimento
Henrique da Silva Ferrão Nascimento
CCCristina Catarino
Cristina Catarino
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva

30 June 2008 in American Journal of Nephrology
Verified
Journal Article
Closed access
Elisio CostaElisio Costa
Elisio Costa
Susana RochaSusana Rocha
Susana Rocha
PRPetronila Rocha-Pereira
Petronila Rocha-Pereira
HNHenrique da Silva Ferrão Nascimento
Henrique da Silva Ferrão Nascimento
ECElisabeth Castro
Elisabeth Castro
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
The aim of this work was to evaluate the neutrophil activation state in chronic kidney disease (CKD) patients under hemodialysis, and its linkage with resistance to recombinant human erythropoietin (rhEPO) therapy. We studied 63 CKD patients under hemodialysis and rhEPO treatment (32 responders and 31 non-responders to rhEPO therapy). In 20 of the CKD patients (10 responders and 10 non-responders to rhEPO therapy), blood samples were also collected immediately after dialysis. Twenty-six healthy volunteers were included in a control group. Hemoglobin levels, total and differential leukocyte counts, and circulating levels of C-reactive protein (CRP), elastase and lactoferrin were measured in all patients and controls. Compared with controls, CKD patients presented with significantly higher CRP, neutrophil and elastase levels. When we compared the 2 groups of patients, we found that non-responders presented statistically significantly higher elastase plasma levels. A positive significant correlation was found between elastase levels and weekly rhEPO dose and CRP serum levels. After the hemodialysis procedure, a statistically significant rise in elastase, lactoferrin and, elastase/neutrophil and lactoferrin/neutrophil ratios were found. Our data show that CKD patients under hemodialysis present higher elastase levels (particularly in non-responding patients), which could be related to the rise in neutrophils, and to be part of the enhanced inflammatory process found in these patients.